Immutep Limited (NASDAQ:IMMP – Get Free Report) shares crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $2.28 and traded as low as $1.91. Immutep shares last traded at $1.95, with a volume of 48,963 shares.
Analyst Ratings Changes
Separately, Robert W. Baird cut their price objective on Immutep from $7.00 to $6.00 and set an “outperform” rating on the stock in a research note on Thursday, June 27th.
Check Out Our Latest Stock Analysis on Immutep
Immutep Stock Performance
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in the business. XTX Topco Ltd acquired a new stake in Immutep during the second quarter worth approximately $26,000. BNP Paribas Financial Markets lifted its position in shares of Immutep by 15.4% during the 1st quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company’s stock valued at $82,000 after acquiring an additional 4,700 shares during the period. XY Capital Ltd bought a new position in Immutep during the second quarter worth $105,000. Virtu Financial LLC grew its holdings in Immutep by 269.4% in the first quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 32,864 shares during the period. Finally, Oracle Investment Management Inc. increased its stake in Immutep by 9.4% in the first quarter. Oracle Investment Management Inc. now owns 564,879 shares of the biotechnology company’s stock valued at $1,316,000 after purchasing an additional 48,449 shares in the last quarter. 2.32% of the stock is owned by institutional investors.
Immutep Company Profile
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.
Further Reading
- Five stocks we like better than Immutep
- What is a Special Dividend?
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Manufacturing Stocks Investing
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Immutep Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immutep and related companies with MarketBeat.com's FREE daily email newsletter.